Exelixis Inc Reimbursement Revenue (Deprecated 2018-01-31)
Exelixis Inc (EXEL) reported Reimbursement Revenue (Deprecated 2018-01-31) of $0 for the 12-month period ending 2012-12-31, per its 10-K filed 2013-02-21.
Discontinued › Income Statement › Other Income
us-gaap:ReimbursementRevenue · last filed 2013-02-21
- Exelixis Inc reimbursement revenue (deprecated 2018-01-31) for the quarter ending 2012-12-31 was $0.00, a 100.00% decline year-over-year.
- Exelixis Inc reimbursement revenue (deprecated 2018-01-31) for the quarter ending 2012-09-30 was $0.00, a 100.00% decline year-over-year.
- Exelixis Inc reimbursement revenue (deprecated 2018-01-31) for the quarter ending 2012-06-30 was $0.00, a 100.00% decline year-over-year.
- Exelixis Inc reimbursement revenue (deprecated 2018-01-31) for the quarter ending 2012-03-31 was $0.00, a 100.00% decline year-over-year.
- Exelixis Inc reimbursement revenue (deprecated 2018-01-31) for fiscal 2012 was $0.00, a 100.00% decline from fiscal 2011.
- Exelixis Inc reimbursement revenue (deprecated 2018-01-31) for fiscal 2011 was $2.78M, a 89.87% decline from fiscal 2010.
- Exelixis Inc reimbursement revenue (deprecated 2018-01-31) for fiscal 2010 was $27.41M.
- Exelixis Inc reimbursement revenue (deprecated 2018-01-31) for fiscal 2009 was -$4.58M.
| Period end | Reimbursement Revenue (Deprecated 2018-01-31) 3 month | Reimbursement Revenue (Deprecated 2018-01-31) 6 month | Reimbursement Revenue (Deprecated 2018-01-31) 9 month | Reimbursement Revenue (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $0.00 derived: sum of 2 quarters · filed 2013-02-21 | $0.00 derived: sum of 3 quarters · filed 2013-02-21 | $0.00 10-K · filed 2013-02-21 |
| 2012-09-30 | $0.00 10-Q · filed 2012-11-07 | $0.00 derived: sum of 2 quarters · filed 2012-11-07 | $0.00 10-Q · filed 2012-11-07 | $195.00K derived: sum of 4 quarters · filed 2013-02-21 |
| 2012-06-30 | $0.00 10-Q · filed 2012-08-02 | $0.00 10-Q · filed 2012-08-02 | $195.00K derived: sum of 3 quarters · filed 2013-02-21 | $740.00K derived: sum of 4 quarters · filed 2013-02-21 |
| 2012-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2013-02-21 | $195.00K derived: sum of 2 quarters · filed 2013-02-21 | $740.00K derived: sum of 3 quarters · filed 2013-02-21 | $2.08M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-12-31 | $195.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $740.00K derived: sum of 2 quarters · filed 2013-02-21 | $2.08M derived: sum of 3 quarters · filed 2013-02-21 | $2.78M 10-K · filed 2013-02-21 |
| 2011-09-30 | $545.00K 10-Q · filed 2012-11-07 | $1.89M derived: sum of 2 quarters · filed 2012-11-07 | $2.58M 10-Q · filed 2012-11-07 | $3.29M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-06-30 | $1.34M 10-Q · filed 2012-08-02 | $2.04M 10-Q · filed 2012-08-02 | $2.74M derived: sum of 3 quarters · filed 2013-02-21 | $20.81M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-03-31 | $694.00K 10-Q · filed 2012-05-03 | $1.40M derived: sum of 2 quarters · filed 2013-02-21 | $19.47M derived: sum of 3 quarters · filed 2013-02-21 | $30.21M derived: sum of 4 quarters · filed 2013-02-21 |
| 2010-12-31 | $705.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $18.77M derived: sum of 2 quarters · filed 2013-02-21 | $29.52M derived: sum of 3 quarters · filed 2013-02-21 | $27.41M 10-K · filed 2013-02-21 |
| 2010-09-30 | $18.07M 10-Q · filed 2011-10-27 | $28.81M derived: sum of 2 quarters · filed 2011-10-27 | $26.71M 10-Q · filed 2011-10-27 | |
| 2010-06-30 | $10.75M 10-Q · filed 2011-08-04 | $8.64M 10-Q · filed 2011-08-04 | ||
| 2009-12-31 | -$4.58M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |